Search
Search Constraints
You searched for: Date 2019 Author/Creator Propper, DavidLimit your search
- 616.994 1
- 95% CI 95% confidence interval -- BSC best supportive care -- BTC biliary tract cancer -- CCA cholangiocarcinoma -- CA19-9 carbohydrate antigen 19-9 -- CR complete response -- ECOG Eastern Cooperative Oncology Group -- GEMCIS gemcitabine plus cisplatin -- GEMOX gemcitabine plus oxaliplatin -- HR hazard ratio -- IQR interquartile range -- L1 first-line (treatment) -- L2 second-line (treatment) -- OS overall survival -- PD progressive disease -- PFS progression-free survival -- PR partial response -- PS performance status -- RECIST Response Evaluation Criteria in Solid Tumours -- SD stable disease -- UK United Kingdom 1
- Cancer 1
- Cancer -- Periodicals 1
- Cancer -- Périodiques 1
- Cholangiocarcinoma -- Palliative chemotherapy -- Prognosis -- Prognostic biomarker -- Stratification 1
- Electronic journals 1
- Neoplasms -- Periodicals 1
- Periodicals 1
- Tumors 1